Novo Nordisk insulin Ryzodeg passes Japan review



COPENHAGEN |
Mon Dec 3, 2012 1:58am EST


COPENHAGEN (Reuters) – Denmark’s Novo Nordisk, a world’s biggest insulin producer, pronounced on Monday a Ryzodeg insulin had upheld a initial examination by an advisory cabinet to a health method in Japan.

Novo Nordisk pronounced in a matter it approaching to accept selling authorisation for a diagnosis from a Ministry within a few months.

Price negotiations for another insulin, degludec, continued and were approaching to be finished in a initial entertain of 2013, a association pronounced in a statement, adding a accurate launch timing for Ryzodeg would be motionless after a cost inventory for degludec.

(Reporting by Copenhagen Newsroom; Editing by Hans-Juergen Peters)

More on: Health Medicine Network